We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Salvarx Group Plc | LSE:SALV | London | Ordinary Share | IM00BZ4SS228 | ORD 2.5P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 4.50 | 0.00 | 00:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
From Mar 2020 to Mar 2025
TIDMSALV
RNS Number : 1025I
SalvaRx Group plc
21 November 2018
SalvaRx Group plc
("SalvaRx", the "Company" or the "Group")
Transaction Update
Further to the announcements of 14 and 28 August 2018 relating to the proposed disposal of the Company's 94.2% interest in SalvaRx Limited to Portage Biotech Inc. ("Portage"), the Company is pleased to announce that the Portage shareholder meeting to approve the transaction has been set for 8 January 2019 and meeting materials will be sent to Portage shareholders on the Portage record date, being 23 November 2018. Trading in Portage shares on the Canadian Securities Exchange is expected to resume shortly after the meeting materials have been posted.
The Company will now finalise and publish its shareholder circular and a further announcement will be made by the Company in due course.
Enquiries
SalvaRx Group plc Ian Walters (Chief Executive) Tel: +1 203-441-5451 Northland Capital Partners Limited Tel: +44 (0) 20 Nominated Adviser and Broker 3861 6625 Matthew Johnson / Edward Hutton (Corporate Finance) Vadim Alexandre (Corporate Broking) Peterhouse Capital Limited Tel: +44 (0) 20 Joint Broker 7469 0932 Lucy Williams / Duncan Vasey
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
DISPGGGAGUPRGPG
(END) Dow Jones Newswires
November 21, 2018 08:00 ET (13:00 GMT)
1 Year Salvarx Chart |
1 Month Salvarx Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
